The Parc Taulí Urology Service and Laboratory Service have incorporated the 'Select MDx' genetic test to detect patients at risk of high-grade prostate cancer. This test is based on the study of biomarkers present in the patient's urine which, together with a number of clinical and analytical parameters, provide the patient's risk of developing high-grade prostate cancer.
High-grade prostate cancer is the most aggressive and deadly, with a prevalence of 50-60 new cases each year per 100.000 population. About 150 cases of prostate cancer are diagnosed each year at Parc Taulí.
This test is indicated for patients with suspected prostate cancer, no biopsy, or a previous negative prostate biopsy, to increase test performance and decrease the number of unnecessary biopsies. 'Select MDx' is a quick, easy and reliable test to rule out prostate cancer. For Dr. Jesús Muñoz, urologist at Parc Taulí, “The use of this test helps to assess which patients with high PSA values should undergo a biopsy. Therefore, it helps to avoid unnecessary prostate biopsies, both initial and repeated, an invasive procedure that is not without complications such as infection or bleeding.
For his part, the coordinator of the Laboratory Service, Dr. Francesc Campos stands out “The importance in people's quality of life, derived both from the reduction in the number of biopsies and from the anxiety caused by the diagnosis of a neoplasm and the adverse effects of the treatments that the patient may receive without having an impact on their survival ”.
Leave a Reply